<DOC>
	<DOCNO>NCT02542111</DOCNO>
	<brief_summary>This study evaluate efficacy safety Bortezomib plus GDP treatment non-GCB DLBCL patient .</brief_summary>
	<brief_title>A Study Bortezomib Plus GDP Treatment Refractory Relapsed Non-GCB DLBCL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>1 . Histologically proven diffuse large Bcell lymphoma nonGCB subtype . Previously treat 1 , 1 , chemotherapy regimen include anthracycline exclude cisplatin , cytarabine , bortezomib gemcitabine . Relapse CR , less PR PR previous treatment . 2 . No history stem cell transplantation , intention stem cell transplantation . 3 . Age 1675 . 4 . ECOG &lt; 3 . 5 . At least 1 measurable tumor mass . 6 . Minimum life expectancy 3 month . 7 . Written informed consent . 8 . No uncontrolled CNS involvement lymphoma : No CNS disease time relapse ; CNS disease diagnose initial presentation allow provide complete response CNS disease achieve maintain . 1 . Chemotherapy large field radiotherapy within 3 week prior enter study . 2 . Clinically significant active infection . 3 . Impaired liver , renal organ function cause lymphoma , interfere treatment schedule . 4 . Any significant medical psychiatric condition might prevent patient comply study procedure . 5 . Subject â‰¥grade 2 peripheral neuropathy grade 1 pain within 14 day enrollment . 6 . Patients pregnant breastfeeding . 7 . HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>diffuse large b-cell lymphoma</keyword>
</DOC>